S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Is Hanes Worth More than the Sum of Its Parts?
NASDAQ:ETNB

89bio (ETNB) Competitors

$15.23
-0.71 (-4.45%)
(As of 09/25/2023 ET)
Compare
Today's Range
$14.98
$15.87
50-Day Range
$15.07
$17.78
52-Week Range
$4.96
$22.93
Volume
1.83 million shs
Average Volume
989,968 shs
Market Capitalization
$1.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.44

ETNB vs. AMLX, MRUS, XNCR, ANIP, OPK, BHVN, KNSA, AUPH, SAGE, and DAWN

Should you be buying 89bio stock or one of its competitors? The main competitors of 89bio include Amylyx Pharmaceuticals (AMLX), Merus (MRUS), Xencor (XNCR), ANI Pharmaceuticals (ANIP), OPKO Health (OPK), Biohaven (BHVN), Kiniksa Pharmaceuticals (KNSA), Aurinia Pharmaceuticals (AUPH), Sage Therapeutics (SAGE), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical preparations" industry.

89bio vs.

89bio (NASDAQ:ETNB) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, community ranking, risk, earnings, dividends and valuation.

89bio has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.93, indicating that its share price is 193% less volatile than the S&P 500.

89bio currently has a consensus price target of $37.44, indicating a potential upside of 145.86%. Amylyx Pharmaceuticals has a consensus price target of $49.40, indicating a potential upside of 163.89%. Given Amylyx Pharmaceuticals' higher possible upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than 89bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
89bio
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Amylyx Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

89bio has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
89bioN/AN/A-$102.03M-$2.11-7.22
Amylyx Pharmaceuticals$22.23M56.74-$198.38M-$1.24-15.10

89bio received 65 more outperform votes than Amylyx Pharmaceuticals when rated by MarketBeat users. However, 72.00% of users gave Amylyx Pharmaceuticals an outperform vote while only 61.48% of users gave 89bio an outperform vote.

CompanyUnderperformOutperform
89bioOutperform Votes
83
61.48%
Underperform Votes
52
38.52%
Amylyx PharmaceuticalsOutperform Votes
18
72.00%
Underperform Votes
7
28.00%

89bio has a net margin of 0.00% compared to Amylyx Pharmaceuticals' net margin of -37.95%. Amylyx Pharmaceuticals' return on equity of -23.80% beat 89bio's return on equity.

Company Net Margins Return on Equity Return on Assets
89bioN/A -39.80% -34.28%
Amylyx Pharmaceuticals -37.95%-23.80%-20.30%

87.7% of Amylyx Pharmaceuticals shares are owned by institutional investors. 4.4% of 89bio shares are owned by insiders. Comparatively, 11.8% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, 89bio had 7 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 9 mentions for 89bio and 2 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.75 beat 89bio's score of 0.44 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
89bio
2 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Amylyx Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Amylyx Pharmaceuticals beats 89bio on 9 of the 16 factors compared between the two stocks.


Get 89bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for ETNB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ETNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ETNB vs. The Competition

Metric89bioPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.15B$5.06B$4.39B$6.29B
Dividend YieldN/A2.65%5.90%9.76%
P/E Ratio-7.227.82149.6113.67
Price / SalesN/A151.082,843.7156.11
Price / CashN/A19.6321.7222.67
Price / Book5.083.813.814.68
Net Income-$102.03M$174.86M$121.81M$185.66M
7 Day Performance-8.86%-3.51%-1.73%-2.09%
1 Month Performance-7.81%-8.68%-3.33%-4.44%
1 Year Performance191.20%7.43%9.55%6.02%

89bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMLX
Amylyx Pharmaceuticals
2.6534 of 5 stars
$18.88
+1.0%
$49.40
+161.7%
-32.8%$1.27B$22.23M-15.23338Positive News
MRUS
Merus
1.8241 of 5 stars
$24.98
+0.4%
$44.33
+77.5%
+21.0%$1.25B$41.59M-6.47164
XNCR
Xencor
1.921 of 5 stars
$21.10
+2.2%
$44.20
+109.5%
-19.3%$1.28B$164.58M-9.86281Positive News
ANIP
ANI Pharmaceuticals
2.5477 of 5 stars
$61.08
-0.6%
$71.67
+17.3%
+83.5%$1.24B$316.39M-127.25600
OPK
OPKO Health
2.369 of 5 stars
$1.66
+2.5%
$3.85
+131.9%
-14.9%$1.28B$1.00B-6.154,196Positive News
BHVN
Biohaven
2.3625 of 5 stars
$18.07
-1.1%
$25.25
+39.7%
-88.6%$1.23B$462.51M-2.44928Positive News
KNSA
Kiniksa Pharmaceuticals
1.9043 of 5 stars
$17.54
+1.2%
$20.00
+14.0%
+49.4%$1.23B$220.18M5.36220Positive News
AUPH
Aurinia Pharmaceuticals
1.9019 of 5 stars
$8.56
+1.9%
$13.33
+55.8%
+15.4%$1.23B$134.03M-17.12300Positive News
SAGE
Sage Therapeutics
2.4665 of 5 stars
$20.45
+0.7%
$43.57
+113.1%
-50.0%$1.22B$7.69M-2.06689
DAWN
Day One Biopharmaceuticals
1.5909 of 5 stars
$14.06
+0.1%
$42.14
+199.7%
-29.9%$1.22BN/A-6.14124

Related Companies and Tools

This page (NASDAQ:ETNB) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -